These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35244407)

  • 1.
    Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
    Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive evaluation of PD-L1 expression in non-small cell lung cancer by immunoPET imaging using an acylating agent-modified antibody fragment.
    Cheng Y; Shi D; Ye R; Fu W; Ma P; Si Z; Xu Z; Li L; Lin Q; Cheng D
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1585-1596. PubMed ID: 36759371
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Bridgwater C; Geller A; Hu X; Burlison JA; Zhang HG; Yan J; Guo H
    Cancer Biother Radiopharm; 2020 Oct; 35(8):549-557. PubMed ID: 32315549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
    Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
    Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Evaluation of
    Shi D; Fu W; Tan H; Lin Q; Shi H; Cheng D
    Mol Pharm; 2024 Jan; 21(1):303-312. PubMed ID: 38109713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive Evaluation of CD20 Expression Using
    Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
    J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung Cancer.
    Smit J; Borm FJ; Niemeijer AN; Huisman MC; Hoekstra OS; Boellaard R; Oprea-Lager DE; Vugts DJ; van Dongen GAMS; de Wit-van der Veen BJ; Thunnissen E; Smit EF; de Langen AJ
    J Nucl Med; 2022 May; 63(5):686-693. PubMed ID: 34385342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical evaluation and pilot clinical study of [
    Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of
    Bouleau A; Nozach H; Dubois S; Kereselidze D; Chevaleyre C; Wang CI; Evans MJ; Lebon V; Maillère B; Truillet C
    J Nucl Med; 2022 Aug; 63(8):1259-1265. PubMed ID: 34933891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Biologic Evaluation of a Novel
    Donnelly DJ; Smith RA; Morin P; Lipovšek D; Gokemeijer J; Cohen D; Lafont V; Tran T; Cole EL; Wright M; Kim J; Pena A; Kukral D; Dischino DD; Chow P; Gan J; Adelakun O; Wang XT; Cao K; Leung D; Bonacorsi SJ; Hayes W
    J Nucl Med; 2018 Mar; 59(3):529-535. PubMed ID: 29025984
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Kang L; Li C; Yang Q; Sutherlin L; Wang L; Chen Z; Becker KV; Huo N; Qiu Y; Engle JW; Wang R; He C; Jiang D; Xu X; Cai W
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1470-1481. PubMed ID: 34677626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Imaging of the Programmed Death Ligand 1 by
    González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL
    J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with
    Hegi-Johnson F; Rudd SE; Wichmann C; Akhurst T; Roselt P; Trinh J; John T; Devereux L; Donnelly PS; Hicks R; Scott AM; Steinfort D; Fox S; Blyth B; Parakh S; Hanna GG; Callahan J; Burbury K; MacManus M
    BMJ Open; 2022 Nov; 12(11):e056708. PubMed ID: 36400733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive PET imaging of tumor PD-L1 expression with
    Malih S; Lin W; Tang Z; DeLuca MC; Engle JW; Alirezapour B; Cai W; Rasaee MJ
    Am J Nucl Med Mol Imaging; 2024; 14(1):31-40. PubMed ID: 38500749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
    Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
    Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
    Shirasawa M; Yoshida T; Imabayashi T; Okuma K; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Tsuchida T; Yamamoto N; Nakayama Y; Watanabe SI; Motoi N; Ohe Y
    Eur J Cancer; 2022 Feb; 162():1-10. PubMed ID: 34936940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
    Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
    Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
    Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
    J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.